Summary & Overview

Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

DRG 656 encompasses kidney and ureter surgical procedures performed for neoplasm when a Major Complication or Comorbidity is present, affecting clinical complexity and resource needs. Accurate capture of principal diagnosis, procedure codes, and Major Complication or Comorbidity status matters for inpatient reimbursement under Medicare Severity Diagnosis-Related Group-based payment.

Kidney and Ureter Procedures for Neoplasm with MCCDRG Kidney and Ureter Procedures for Neoplasm with MCCDRG 656Diagnosis-Related GroupInpatient ReimbursementMedicareUrologyNephrectomyOncology

DRG 656 Overview

DRG 656 covers inpatient admissions for kidney and ureter procedures performed for neoplasm when a Major Complication or Comorbidity is present. This Diagnosis-Related Group typically includes partial or radical nephrectomy and other urologic tumor resections complicated by significant acute or chronic conditions that increase resource use. It matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates relative weight and reimbursement compared with lower-severity groups. Hospitals and coders must correctly capture principal diagnosis, procedure codes, and accompanying Major Complication or Comorbidity to determine appropriate Medicare Severity Diagnosis-Related Group assignment.

Clinical Trials

Perioperative and intraoperative care optimization trials focused on reducing surgical morbidity for nephrectomy patients with renal neoplasms and major complications: these studies evaluate protocols such as enhanced recovery after surgery (ERAS) pathways, blood loss minimization strategies, and perioperative monitoring in patients undergoing partial or radical nephrectomy complicated by severe comorbid conditions. The patient population includes adults with kidney or upper-tract tumors who present with physiological instability, tumor-related hemorrhage, or require complex reconstruction; outcomes measured include complication rates, length of stay, ICU utilization, and short-term mortality. This research matters to providers and payers because it targets interventions that can lower high-cost postoperative complications and readmissions typical in DRG 656, thereby improving resource use and clinical outcomes.
Comparative effectiveness trials of surgical approaches and extent of resection for malignant kidney and ureter tumors with major complications: these studies compare open versus minimally invasive (laparoscopic/robotic) approaches, nephron-sparing versus radical procedures, or staged versus immediate definitive surgery specifically in patients presenting with tumor-related complications such as invasion, infection, or obstruction. The enrolled population comprises patients with high-risk renal or ureteral neoplasms whose operative complexity and MCCs may influence margin status, renal function preservation, and perioperative morbidity; endpoints include oncologic control, renal functional outcomes, complication profiles, and total hospitalization costs. Results inform surgeons, hospital administrators, and payers about which operative strategies provide the best balance of clinical effectiveness and cost-efficiency for this high-acuity DRG cohort.
Post-discharge outcomes, rehabilitation, and transitional care studies addressing functional recovery, renal replacement needs, and readmission prevention after complex kidney/ureter cancer surgery with MCC: these observational cohorts and interventional trials test discharge planning models, early outpatient monitoring, home-based nursing or telehealth follow-up, and criteria for early initiation of dialysis when indicated. They focus on survivors of complicated nephrectomy or ureteral cancer surgery who have acute kidney injury, decreased baseline renal reserve, or other major complications that increase risk of readmission and long-term dialysis dependence; measured outcomes include 30- and 90-day readmissions, progression to chronic kidney disease or dialysis, patient-reported functional status, and post-acute care utilization. Findings are directly relevant to payers and care managers aiming to reduce costly readmissions and long-term dialysis expenditures while improving continuity of care for this vulnerable DRG population.

Clinical Trials

Perioperative and intraoperative care optimization trials focused on reducing surgical morbidity for nephrectomy patients with renal neoplasms and major complications: these studies evaluate protocols such as enhanced recovery after surgery (ERAS) pathways, blood loss minimization strategies, and perioperative monitoring in patients undergoing partial or radical nephrectomy complicated by severe comorbid conditions. The patient population includes adults with kidney or upper-tract tumors who present with physiological instability, tumor-related hemorrhage, or require complex reconstruction; outcomes measured include complication rates, length of stay, ICU utilization, and short-term mortality. This research matters to providers and payers because it targets interventions that can lower high-cost postoperative complications and readmissions typical in DRG 656, thereby improving resource use and clinical outcomes.
Comparative effectiveness trials of surgical approaches and extent of resection for malignant kidney and ureter tumors with major complications: these studies compare open versus minimally invasive (laparoscopic/robotic) approaches, nephron-sparing versus radical procedures, or staged versus immediate definitive surgery specifically in patients presenting with tumor-related complications such as invasion, infection, or obstruction. The enrolled population comprises patients with high-risk renal or ureteral neoplasms whose operative complexity and MCCs may influence margin status, renal function preservation, and perioperative morbidity; endpoints include oncologic control, renal functional outcomes, complication profiles, and total hospitalization costs. Results inform surgeons, hospital administrators, and payers about which operative strategies provide the best balance of clinical effectiveness and cost-efficiency for this high-acuity DRG cohort.
Post-discharge outcomes, rehabilitation, and transitional care studies addressing functional recovery, renal replacement needs, and readmission prevention after complex kidney/ureter cancer surgery with MCC: these observational cohorts and interventional trials test discharge planning models, early outpatient monitoring, home-based nursing or telehealth follow-up, and criteria for early initiation of dialysis when indicated. They focus on survivors of complicated nephrectomy or ureteral cancer surgery who have acute kidney injury, decreased baseline renal reserve, or other major complications that increase risk of readmission and long-term dialysis dependence; measured outcomes include 30- and 90-day readmissions, progression to chronic kidney disease or dialysis, patient-reported functional status, and post-acute care utilization. Findings are directly relevant to payers and care managers aiming to reduce costly readmissions and long-term dialysis expenditures while improving continuity of care for this vulnerable DRG population.

OpenPayer

Summary & Overview

Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

DRG 656 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes